About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in California | 691 Studies

Clinical Trials MelanomaCalifornia

Melanoma Clinical Trials in California

Find 691 clinical trials for melanoma near California. Connect with research centers in your area.

All Melanoma trials nationwide All trials in California

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 201-220 of 691 trials

CompletedMobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer SurvivorsEvaluate the impact and satisfaction of Mobile Mindfulness Meditation on anxiety, pain, fatigue, trauma, and sleep in cancer survivors.NCT03581357·Palo Alto, California and 1 other CompletedFT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint…NCT03841110·San Diego, California and 3 others CompletedA Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with…NCT01006980·Birmingham, Alabama and 110 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTo characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.NCT02974725·San Diego, California and 31 others

UnknownDose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult…NCT03634982·Scottsdale, Arizona and 11 others

CompletedSafety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat MelanomaThis research study involves two investigational drugs, an Activator Ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001).NCT01397708·Los Angeles, California and 8 others

WithdrawnPhase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaThis study was a mixed phase Ib/II, multi-center, open-label study of tebentafusp (IMCgp100) as a single agent, and in combination with durvalumab and/or tremelimumab, in…NCT02535078·Los Angeles, California and 3 others

TerminatedPembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaThe primary objectives of the Phase 1b part of the study are to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in…NCT02263508·Birmingham, Alabama and 160 others

CompletedBiological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other TumorsRATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing.NCT00003750·Little Rock, Arkansas and 58 others

CompletedVaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant MelanomaRATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells.NCT00039325·Los Angeles, California

CompletedAnti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerThis study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab…NCT04121676·Los Angeles, California and 11 others

CompletedStudy to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF InhibitorMEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive…NCT01037127·Los Angeles, California and 9 others

RecruitingEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsThe trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the…NCT03567889·Phoenix, Arizona and 36 others

CompletedStudy of CP-675,206 in Refractory MelanomaCP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes.NCT00254579·Scottsdale, Arizona and 64 others

TerminatedTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaThis phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor…NCT01495988·Los Angeles, California and 13 others

CompletedEvaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic MelanomaThe primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma.NCT00066196·Scottsdale, Arizona and 24 others

CompletedImatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryThis phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.NCT00470470·Los Angeles, California and 7 others

CompletedDERM US and EU Validation StudyThis study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to…NCT05126173·Redwood City, California and 15 others

CompletedPhase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to…NCT01844505·Gilbert, Arizona and 149 others

TerminatedAn Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain MetastasisThis is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in…NCT03911869·Los Angeles, California and 24 others

PreviousPage 11 of 35Next

Other Conditions in California

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma